EZH2, a unique marker of malignancy in effusion cytology.


Distinguishing reactive mesothelial cells from metastatic disease, typically adenocarcinoma, in effusion cytology can be challenging at times. We currently use a panel of immunocytochemical markers for select cases including MOC-31 and BerEp4, but difficulties still exist. Enhancer of zeste homologue 2 (EZH2) plays important roles in epigenetic silencing… (More)
DOI: 10.1002/dc.22999


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics